Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
GTC Biotherapeutics Inc (GTCB)    
$0.37 0.04 (9.76%) as of 4:30 Wed 7/28


Download
   
Exchange: Nasdaq Small Cap
Security Type: Common
Shares Out: 24,740,000 as of 12/25
Market Cap: 9.15(M)
Last Volume: 4,357 Avg Vol: 34,038
52 Week Range: $0.35 - $2.21
Level I Sector: Health Care
Level II Sector:   Drugs
Level III Sector:      Biotechnology

Member Indexes:
    NASDAQ COMPOSITE       NASDAQ NNM COMPOSITE  

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

              1 Year   2 Year  
 
 

Company Profile   GTC Biotherapeutics develops and produces human therapeutic proteins through transgenic technology that provides production of therapeutic proteins in the milk of transgenic mammals. As of Dec 31 2006, Co.'s proprietary products and product candidates in development includes ATryn? which is a recombinant form of human antithrombin; rhFVIIa which is a blood coagulation factor; rhAAT which is an inhibitor of elastase; and CD137 which is involved in the initiation and regulation of the human immune system. In addition, Co. has external program under contract with Merrimack Pharmaceuticals, Inc., for transgenic production and purification of Merrimack's recombinant human alpha-fetoprotein.

 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 14,798 3,402,649 3,488,649
Total Buy Value $0 $15,982 $3,640,983 $3,655,164
Total People Bought 0 1 2 3
Total Buy Transactions 0 1 2 3
Total Shares Sold 0 0 14,798 14,798
Total Sell Value $0 $0 $16,648 $16,648
Total People Sold 0 0 1 1
Total Sell Transactions 0 0 1 1
End Date 2010-04-25 2010-01-22 2009-07-24 2008-07-24

   
Records found: 235
  Page 1 of 10  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Mcnamara Pamela W Director   –       •      –    2010-07-02 4 A $0.46 $1,000 D/D 2,174 8,494     -
   Tuck Alan W Director   –       •      –    2010-07-02 4 A $0.46 $1,500 D/D 3,261 12,109     -
   Bullock Francis J Director   –       •      –    2010-07-02 4 A $0.46 $1,875 D/D 4,076 15,367     -
   Mcnamara Pamela W Director   –       •      –    2010-04-01 4 A $0.55 $1,000 D/D 1,818 6,320     -
   Tuck Alan W Director   –       •      –    2010-04-01 4 A $0.55 $1,500 D/D 2,727 8,848     -
   Scotland Richard A Senior VP, Regulatory Affairs   •       –      –    2010-02-09 4 B $1.08 $15,982 I/I 14,798 14,798 1.99 -53%     
   Scotland Richard A Senior VP, Regulatory Affairs   •       –      –    2010-01-19 4 S $1.13 $16,648 I/I (14,798) 0 61%     
   Lfb Biotechnologies S.a.s.u. Director by Deputization   –       •       •   2010-01-06 4 OE $2.24 $12,749,996 D/D 5,299,071 21,299,906     -
   Bullock Francis J Director   –       •      –    2009-12-31 4 A $0.75 $1,875 D/D 2,500 7,882     -
   Mcnamara Pamela W Director   –       •      –    2009-12-31 4 A $0.75 $1,000 D/D 1,333 4,502     -
   Tuck Alan W Director   –       •      –    2009-12-31 4 A $0.75 $1,500 D/D 2,000 6,121     -
   Geraghty James A Director   –       •      –    2009-12-31 4 A $0.75 $3,000 D/D 4,000 19,025     -
   Woloshen Daniel S Senior VP and General Counsel   •       –      –    2009-11-02 4/A A $1.21 $15,834 D/D 13,086 23,402     -
   Green John B Senior VP and CFO   •       –      –    2009-11-02 4 A $1.21 $16,604 D/D 13,722 28,173     -
   Cox Geoffrey F President, CEO and Chairman   •       •      –    2009-11-02 4 A $1.21 $38,267 D/D 31,626 87,944     -
   Lfb Biotechnologies S.a.s.u. Director by Deputization   –       •       •   2009-11-02 4 B $1.07 $3,625,001 D/D 3,387,851 16,000,835 3.92 -11%     
   Scotland Richard A Senior VP, Regulatory Affairs   •       –      –    2009-11-02 4 A $1.21 $13,634 D/D 11,268 21,899     -
   Meade Harry SVP, Transgenic Research   •       –      –    2009-11-02 4 A $1.21 $16,454 D/D 13,598 29,452     -
   Woloshen Daniel S Senior VP and General Counsel   •       –      –    2009-11-02 4/A D $1.21 $5,066 D/D (4,187) 19,215     -
   Meade Harry SVP, Transgenic Research   •       –      –    2009-11-02 4/A A $1.21 $18,638 D/D 15,403 31,257     -
   Meade Harry SVP, Transgenic Research   •       –      –    2009-11-02 4/A D $1.21 $6,679 D/D (5,520) 25,737     -
   Woloshen Daniel S Senior VP and General Counsel   •       –      –    2009-11-02 4 A $1.21 $14,178 D/D 11,717 22,033     -
   Scotland Richard A Senior VP, Regulatory Affairs   •       –      –    2009-11-02 4/A D $1.21 $7,754 D/D (6,408) 17,587     -
   Scotland Richard A Senior VP, Regulatory Affairs   •       –      –    2009-11-02 4/A A $1.21 $16,170 D/D 13,364 23,995     -
   Green John B Senior VP and CFO   •       –      –    2009-11-02 4/A D $1.21 $6,760 D/D (5,587) 24,413     -
  235 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 10
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2009 J3SG.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us